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Abstract
Background and purpose: Higher cardiac dose was associated with worse overall survival in 
the RTOG0617 study. Pericardial effusion (PCE) is a common cardiac complication of thoracic 
radiation therapy (RT). We investigated whether doses of radiation to the heart and pericardium are 
associated with PCE and overall survival in patients treated with thoracic radiation for non-small 
cell lung cancer (NSCLC).
Materials and Methods: A total of 94 patients with medically inoperable/unresectable NSCLC 
treated with definitive RT in prospective studies were reviewed for this secondary analysis. Heart 
and pericardium were contoured consistently according to the RTOG1106 Atlas, with the great 
vessels and thymus of the upper mediastinal structures included in the upper part of pericardium, 
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only heart chambers included in the heart structure. Clinical factors and dose-volume parameters 
associated with PCE or survival were identified via Cox proportional hazards modeling. The risk 
of PCE and death were mapped using DVH atlases.
Results: Median follow-up for surviving patients was 58 months. The overall rate of PCE was 
40.4%. On multivariable analysis, dosimetric factors of heart and pericardium were significantly 
associated with the risk of PCE. Pericardial V30 and V55 were significantly correlated with 
overall survival, but presence of PCE and heart dosimetric factors were not.
Conclusion: PCE was associated with both heart and pericardial doses. The significance of 
pericardial dosimetric parameters, but not heart chamber parameters, on survival suggests the 
potential significance of radiation damage to the cranial region of pericardium.
Keywords
NSCLC; Pericardial dose; Heart dose; Pericardial effusion
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide (1). Approximately 
two-thirds of lung cancer patients receive radiation therapy (RT) at least once during the 
course of treatment with either definitive or palliative intent (2). Biological and clinical 
evidence suggest that a higher radiation dose might provide better local tumor control and 
may prolong survival in patients with non-small cell lung cancer (NSCLC) (3). However, 
delivery of higher dose RT also increases the risk of radiation-related damage to organs at 
risk (OARs), including the heart and pericardium (4, 5). Pericardial effusion (PCE) is one of 
the common cardiac toxicity after RT and the rate of PCE has been reported to range from 
20 to 45% (6–8). Unfortunately, studies on PCE and its impact on survival are limited in 
NSCLC. It is unclear whether high-dose radiation to the heart or pericardium contributes to 
poor survival in patients treated with concurrent chemoradiotherapy. RTOG 0617 reported 
that the higher radiation dose (74 Gy) arm had a significantly inferior survival and notably 
higher number of treatment-related deaths, compared to the standard-dose arm (60 Gy) (9, 
10). Un-reported toxicity such as PCE from higher dose irradiation of the heart and 
pericardium may partially contribute to these results (9–11). Several studies have confirmed 
the association of heart dose with inferior survival (12, 13), but other studies did not find a 
significant association (14, 15). We hypothesized that high-dose radiation to the heart/
pericardium has a negative impact on the survival of NSCLC patients treated with radiation. 
Specifically, this study aimed to investigate whether: 1) the dosimetry of the heart and/or 
pericardium is associated with PCE; 2) the presence of PCE or dosimetric factors for the 
heart and/or pericardium correlate with overall survival in patients treated with thoracic RT.
Materials and Methods
Study population
This study included consecutive patients with medically inoperable or unresectable NSCLC 
enrolled on prospective clinical trials from two medical centers (details of the 4 prospective 
trials including the chemotherapy regimen are summarized in Appendix A1) that were 
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approved by their respective institutional review boards. Written informed consent was 
obtained from all patients before enrollment into the trials. All patients had histologically 
proven stage I-III NSCLC and a Karnofsky performance status (KPS) ≥70.
Treatment
All patients received definitive, fractionated radiotherapy with or without concurrent 
chemotherapy. Computed tomography (CT)-based treatment planning was performed on 
simulation scans of the entire thorax. Intravenous contrast-enhanced CT was implemented 
whenever possible. Radiotherapy was mostly delivered using a 3D conformal technique. A 
total dose of 60-85.5 Gy was delivered with 2-3.8 Gy daily fractions given over 6-7 weeks 
using 6-16 MV photons. Tumor delineation was contoured and edited according to the best 
judgment of the treating radiation oncologist. The total dose delivered to the planning target 
volume (PTV) was limited when necessary by tolerance limits of critical organs at risk 
(OARs) per standard practice, or to a mean lung dose of less than 20 Gy or lung normal 
tissue complication probability (NTCP) of less than 15-17.2% for patients treated in dose 
escalation studies. The maximum spinal cord dose was limited to ≤ 50 Gy, maximum 
brachial plexus dose ≤ 66 Gy, heart 1/3 volume ≤ 60 Gy, 2/3 ≤ 45 Gy, and 3/3 ≤ 40 Gy.
Dosimetric analyses of heart and pericardium
The heart and pericardium were outlined on each axial planning CT scans according to the 
RTOG 1106 trial atlas recommendations (http://www.rtog.org/CoreLab/ContouringAtlases/
LungAtlas.aspx). Superiorly, the pericardium started one slice (3 mm) above the superior 
end of the aortic arch, the normal heart started one slice (3 mm) below the pulmonary artery 
trunk passing the midline. Inferiorly, the pericardium and heart are exactly the same, ending 
at the pericardial apex at the diaphragm, with inclusion of all the heart chambers, great 
vessels and coronary vessels, pericardium, and fatty tissue around these structures.
The superior part of pericardium contains fatty tissue, residual thymus and parts of the great 
vessels (e.g. subclavian artery, left carotid artery, innominate artery, ascending aorta, 
descending aorta, pulmonary artery, superior vena cava). Cumulative dose-volume 
histograms (DVHs) of the heart and pericardium were computed from treatment plans using 
UM Plan. Heart and pericardial radiation dose was analyzed as a continuous variable with a 
focus on mean dose, as well as the volumes receiving 5 Gy (V5) , 30 Gy (V30) and 55 Gy 
(V55), as V5 and V30 were significant factors for overall survival in the RTOG 0617 study 
(10) and V55 was selected as a representative point of volume for high dose, which was also 
recently reported as a significant factor for pericardial effusion (7). All computed dosimetric 
factors are physical doses, without consideration of fractionation effect.
Dose-Volume Atlases
As recommended by the QUANTEC group (16, 17), dose-volume atlases were mapped for 
the risk of PCE and death. The format and usage of these files are described in the word file 
in the electronic Appendix A2.
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Follow-up and PCE evaluation
Patients were followed up in the clinic and with chest CT scans at 3, 6, 9, 12, 18, and 24 
months after RT, and yearly thereafter. Additional CT or PET-CT scans were performed as 
clinically indicated. Toxicity was assessed using the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 3.0. The development of a PCE was 
evaluated by follow-up chest CT scans. PCE was measured independently by radiation 
oncologists with confirmation by a report from a radiologist. The time to PCE was 
calculated from the beginning of RT to the date of reported PCE. Patients without PCE were 
censored at death or last follow-up. Overall survival (OS) was calculated from the beginning 
of RT to the date of death or censored to the last follow-up.
Statistical analysis
The primary endpoints of this study were PCE and overall survival. The following factors 
were included in the risk analysis: gender, age, prescribed tumor dose, chemotherapy, 
smoking, chronic obstructive pulmonary disease (COPD), cardiovascular disease (CVD), 
hypertension, histology, karnsofsky performance status (KPS), stage, gross tumor volume 
(GTV) volume, tumor location, as well as mean dose, V5, V30 and V55 of heart and 
pericardium. The correlations between above assessed variables and PCE or OS were 
computed with the Cox proportional hazards model in univariable and multivariable 
analyses. A univariable P value of 0.05 was defined as the threshold at which to select 
parameters for multivariable analysis. The X-tile software (Version 3.6.1, Yale University, 
New Haven, CT, USA) was used to determine the optimal cut-off values of identified 
covariates for overall survival. Log-rank tests were then performed using the cut-off splits 
for each variable. Analyses were carried out using SPSS 17.0 software and p<0.05 was 
considered significant.
Results
A total of 94 patients were eligible and their characteristics are shown in Table 1. Median 
age was 66 years (range, 43-85 years). Seventy-eight patients (83.0%) were male, 71 
(75.5%) had centrally located primary tumors, and 76 (80.9%) had stage III disease. 
Chemotherapy was administered to 79 (84.0%) patients. The median prescribed radiation 
dose was 70 Gy (range, 45-85.5 Gy) and the median gross tumor volume (GTV) was 129.6 
cc (range, 2.1–802.9 cc). The median mean dose and maximum dose to the heart were 13.9 
Gy (range, 0.2-46.9 Gy) and 72.9 Gy (range, 0.8-99.7 Gy), respectively.
The median follow-up for surviving patients was 58 months (range 44-124). The rate of PCE 
was 40.4% (38 of 94 patients), and the median observed time to onset of PCE was 5.4 
months from the beginning of RT (range, 1.0-24.7 months), as shown in Fig. 1a.
Table 2 lists the clinical and dosimetric factors associated with PCE. Univariable analysis 
demonstrated that prescribed dose, chemotherapy, hypertension and GTV were significantly 
(p<0.05) associated with PCE, while gender, age, smoking status, COPD, CVD, histology, 
KPS, stage and tumor location were not.
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The relationship between DVH parameters of both heart and pericardium (V5-V80) and 
PCE are shown in Fig. 1b. As shown in Table 2, univariable analysis demonstrated that the 
risk of PCE was correlated significantly with all input dosimetric parameters, including heart 
and pericardial mean dose, V5, V30 and V55. The dosimetric parameters were entered into 
the multivariable analysis separately, one by one, not together, as they were strongly linearly 
correlated with each other. Prescription dose, hypertension, heart doses (mean, V5 and V55) 
and pericardial doses (mean, V5, V30 and V55) remained statistically significant in 
multivariable analysis (Table 2).
The median overall survival for all patients was 22.2 months (Fig. 2a). Under univariable 
Cox analysis, the development of PCE was not significantly associated with survival (HR 
0.732, 95% CI 0.458-1.170, p=0.192, Table 3). The log-rank test demonstrated no significant 
difference in survival between patients with and without PCE (median survival 22.2 vs 21.4 
months, p=0.190, Fig. 2b).
Table 3 lists the clinical and dosimetric factors associated with overall survival. Univariable 
analysis demonstrated that gender, prescription dose, KPS, pericardial V30 and V55 were 
significantly correlated with survival, while age, chemotherapy, smoking, COPD, CVD, 
hypertension, histology, stage and tumor location were not significantly associated (Table 3). 
Under multivariable analysis, prescribed dose, KPS, pericardial V30 and V55 remained 
statistically significant (Table 3). Interestingly, the heart doses (mean, V5, V30 and V55) 
were not significantly associated with survival. Since pericardial dosimetric parameters were 
significant factors for survival, X-tile computation demonstrated that the cutoff points for 
pericardial V30 and V55 were 29% and 21%, respectively. Fig. 2c, d shows the difference in 
survival using these pericardial V30 and V55 cutoff values. When the pericardial V30 was ≤ 
29%, overall survival was significantly better. Median survival was 13.3 months and 35.8 
months for patients with pericardial V30 >29% and ≤ 29% (log-rank p=0.003), respectively. 
The difference in survival for patients with pericardial V55 > 21% and ≤ 21% was also 
significant (13.3 months and 30.0 months, respectively; log-rank p=0.013).
Figure 3 show the DVH mapping atlases for PCE and survival. Since multiple dosimetric 
factors were significant, we developed maps of DVH atlases which gave the observed 
complications in DVHs passing above the mapped position. The probability that the true rate 
of PCE >50% and death >75% were picked, and that could produce differences in the 
likelihood across the DVH space. Figures 3a and 3b show maps of probability that the rate 
of PCE is >50%. The increase in this risk with radiation dose to heart/pericardium, 
particularly >35 Gy (red area), is clearly seen. There is also a high risk of PCE for large 
volumes of heart/pericardium exposed to low doses of radiation. Areas of low toxicity 
probability are identified in the lower left of the maps (blue area). Figures 3c and 3d show 
maps of probability that the true rate of death is >75%. High-dose radiation to the 
pericardium, particularly around 55 Gy (orange area), increases the probability of death.
Discussion
PCE is a known radiation-related cardiac toxicity. In our study, the incidence of PCE was 
40.4%, suggesting that PCE may be a common toxicity post-thoracic radiotherapy in 
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NSCLC (18, 19). The high rate of PCE in our series is likely due to our definition based on 
radiographic criteria and to the fact that the majority of patients received concurrent 
chemotherapy. Other factors, including chemotherapy may be associated with the occurrence 
of PCE. Concurrent or induction chemotherapy was found to increase the risk of cardiac 
toxicity, including PCE. In the study of Ning et al., adjuvant chemotherapy, rather than the 
concurrent or induction, was the most strongly associated factor with PCE on multivariate 
analysis(7). Cardiac toxicity has been associated with several chemotherapeutic agents used 
to treat NSCLC, including platinum-based agents (20), taxanes (21), vinorelbine (22) and 
gemcitabine (23). PCE are also reported after the use of targeted therapy (24) and immune 
checkpoint inhibitors (25). In the present study, chemotherapy was a significant risk factor 
for the development of PCE in univariable analysis, but was only of borderline significance 
in multivariable analysis. One possible reason is the relatively small size of this study. It is 
difficult to distinguish the exact role of chemotherapy and dosimetric parameters. We do not 
have enough radiation alone to perform meaningful analysis. But we further analyzed the 
association of dosimetric parameters with PCE in patients treated with concurrent 
chemoradiation by excluding the 15 patients treated with radiation therapy alone. The results 
were similar to the whole group that the all dosimetric parameters were significantly 
associated with inferior survival (electronic Appendix A3). These findings may indicate that 
the chemotherapy may be overshadowed by dosimetric parameters in lung cancer patients 
since large volumes of heart and pericardium often received high-dose irradiation. Future 
study with larger number of cases is needed.
Cardiac dosimetric parameters are widely used to predict the risk of radiation-related cardiac 
toxicities including PCE, though the reported results vary considerably. There is no 
definitive consensus about the most reliable and safe cut-off level because of the strong 
correlations among these dosimetric parameters (26). Some studies have noted that cardiac 
dosimetric parameters, such as mean heart/pericardium dose, max heart/pericardium dose, 
pericardial V30 and total radiation dose to mediastinum, are significantly associated with 
cardiac toxicities with inclusion of PCE (18, 27–30). The present study found that the risk of 
PCE was associated with several cardiac parameters (e,g. mean heart/pericardial dose, heart/
pericardial V5, heart/pericardial V55 and pericardial V30). This is consistent with a recent 
study in which a wide range of cardiac parameters (e.g. V20-V65) predicted the occurrence 
of PCE (7). The DVH atlas analysis also confirmed these associations and more clearly 
illustrated the presentation of high-risk DVHs.
High-dose RT may cause cardiac toxicity, which may offset the benefit of RT and contribute 
to death (11, 31, 32). However, in our study, the presence of PCE was not significantly 
associated with survival. To our knowledge, this is the first study to investigate the 
association between PCE and survival in NSCLC. In our study, pericardial V30 and V55 
were significantly associated with inferior survival on the multivariable analysis, but 
pericardial V55, rather than pericardial V30, was visibly remarkable on the DVH atlas. The 
reason for these conflicting results is unclear, but may be due to the bias of different models, 
and may suggest that the high dose volume of pericardium (V55) is more important than 
lower dose volume (V30) for survival correlates. Nevertheless, our results support the theory 
that minimizing cardiac doses is important in the treatment of NSCLC (9, 11, 33), and 
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suggest that constraining dosimetric factors to minimize radiation to the pericardium, 
specifically limiting pericardial V55 to ≤ 21%, may improve outcomes.
The survival impact of heart dosimetric factors has been controversial. In RTOG 0617, heart 
V5 and V30 significantly correlated with unfavorable survival (9). Stam et al. reported the 
significant associations of heart V5, V30 with overall survival, but not heart V50 (12). The 
other report by Speirs confirmed the association of heart V50 with survival (13). In contrast, 
several recent secondary analyses of randomized trials did not report the association between 
heart doses and overall survival in NSCLC patients receiving RT, even though these factors 
were associated with cardiac toxicity (8, 34–36). Wang et al. reported that the mean dose, 
V5 and V30 of heart/left ventricle were not associated with survival (8), and Guberina et al. 
reported that heart V5 could not be validated as a prognostic factor for survival (34). 
Similarly, a prior study from Michigan reported that heart mean dose, V5, V30 and V50 
were not significantly associated with OS (35). Tucker et al. did not found that the heart dose 
had an independent effect on survival in 468 patients (14). The reason for these conflicting 
results is unclear, but may be partially explained by variations in heart delineations, 
particularly regarding inclusion of full pericardium or not. Indeed, there is no consistent and 
strict definition of heart contour, and most studies did not specify the heart definition. Our 
experience with patients enrolled on RTOG1106 revealed remarkable variations in heart 
definition from institution to institution, despite the trial mandate to use the RTOG atlas 
(posted on website since 2010, with heart contouring ends at one slide before the pulmonary 
trunk passing the midline). Some centers included the full pericardium with inclusion of 
large vessels in the upper mediastinum, while others only included the heart chambers. Since 
the heart is inseparable from the inferior pericardium, the dosimetric parameters of the 
pericardium and heart are significantly correlated with each other, making it difficult to 
determine the individual role of each structure (18). Our study of using RTOG atlas to 
contour heart and pericardium separately, revealed that pericardial doses were associated 
with unfavorable survival, while heart doses were not. This is consistent with a recent study 
by McWilliam et al reporting that radiation dose to heart base (i.e. superior part of 
mediastinum), rather than the conventional heart mean dose, V5 and V30, was associated 
with survival (15). It is also possible that the insignificant correlation of above mentioned 
recent studies (8, 14, 35) contribute to the use of RTOG atlas without inclusion of superior 
mediastinum. This finding suggests that doses to the upper mediastinum may be more 
important than those to the heart chambers. However, studies with larger sample sizes are 
needed to validate this. The biologic reasons underlying these results are unclear, but it is 
possible that radiation to the immune cells in the superior part of pericardial field (e.g. 
residual thymic tissue and lymph nodes) may play a more important role than than the 
cardiac parenchyma in determining radiation-related mortality in NSCLC. This is consistent 
with the recent findings that the effective RT dose to immune structures, rather than the heart 
dose, was the most significant independent negative prognostic factor in RTOG 0617 after 
concurrent chemoradiation, and in early stage NSCLC patients after SBRT treatment (37, 
38).
This study is limited by the relatively small number of patients and the retrospective nature 
of the analysis, although all patients were enrolled into prospective clinical trials. This study 
is also limited by the fact that the dose of RT was computed by an inhouse planning system 
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which no longer a state-of-the-art system. Nevertheless, the results are interesting and 
hypothesis generating, and have immediate clinical relevance.
In summary, PCE is common in patients with stage I-III NSCLC who were treated with 
radiation-based therapy. Several dosimetric factors of both the heart and pericardium are 
significantly associated with the risk of PCE. However, PCE and heart doses are not 
significantly associated with survival, while pericardial doses, particularly V30 and V55, do 
correlate significantly with unfavorable survival. Our data suggest that radiation to the 
pericardium, likely the superior part of the pericardium, may cause lethal toxicity 
independent of the development of PCE. The risk of death may be decreased by minimizing 
the dose of radiation to the pericardium, upper mediastinum. Larger studies are needed to 
validate these findings.
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Highlights:
∎ Pericardial effusion is significantly associated with heart/pericardial 
dosimetric factors.
∎ Pericardial effusion does not have a significant effect on survival.
∎ The irradiated volume of pericardium, rather than the heart dose, is 
associated with inferior survival.
∎ The risk of death may be decreased by minimizing the dose to pericardium.
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Fig.1. 
Pericardial effusion and heart/pericardial dosimetry. (a) Cumulative risk of pericardial 
effusion in 94 patients, (b) Median heart and pericardial dose-volume histograms (DVH) of 
94 patients with or without pericardial effusion (PCE), the color bands represent the 95% CI.
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Fig.2. 
Pericardial effusion and overall survival. (a) Survival curve of all patients. (b) Survival 
difference in patients with or without PCE. (c) Survival difference in patients with 
pericardial V30 > 29% vs. V30 ≤ 29%. (d) Survival difference in patients with pericardial 
V55 > 21% vs. V55 ≤ 21%.
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Fig.3. 
DVH atlases of heart and pericardium. Maps of the probability that the true rate of PCE is 
>50% for DVHs passing over the mapped point in the dose-volume plane, for (a) the heart 
and (b) the pericardium. Maps of probability that the true rate of death is >75% for DVHs 
passing over the mapped point in the dose-volume plane, for (c) the heart and (d) the 
pericardium.
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Table 1
Clinical and dosimetric characteristics of patients
Factors No. of patients (%) Factors No. of patients (%)
Ages CVD
 <=65 43 (45.7%)  no 56 (59.6%)
 >65 51 (54.3%)  yes 38 (40.4%)
Gender Hypertension
 male 78 (83.0%)  no 41 (43.6%)
 female 16 (17.0%)  yes 53 (56.4%)
Stage COPD
 I 11 (11.7%)  no 51 (54.3%)
 II 7 (7.4%)  yes 43 (45.7%)
 III 76 (80.9%) Primary tumor location
Histology  central 71 (75.5%)
 adenocarcinoma 15 (16.0%)  lateral 23 (24.5%)
 squamous cell 31 (33.0%) Prescribed dose (Gy)
 large cell 1 (1.1%)  <70 (median) 35 (37.2%)
 NSCLC NOS 47 (50.0%)  >= 70 (median) 59 (62.8%)
KPS GTV (cc)
 <80 14 (14.9%)  < 129.6 (median) 47 (50.0%)
 >=80 80 (85.1%)  >= 129.6 (median) 47 (50.0%)
Smoking Mean heart dose (Gy)
 no 10 (10.6%)  < 13.9 (median) 47 (50.0%)
 yes 84 (89.4%)  >= 13.9 (median) 47 (50.0%)
Chemotherapy Heart max dose (Gy)
 no 15 (16.0%)  < 72.9 (median) 47 (50.0%)
 yes 79 (84.0%)  >= 72.9 (median) 47 (50.0%)
Abbreviations: COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; NSCLC NOS: non-small cell lung cancer, not 
otherwise specified; KPS: Karnofsky performance status; PCE: pericardial effusion; GTV: gross tumor volume.
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Table 2
Univariable and multivariable cox regression analysis for PCE
Factors
Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Gender 1.494 (0.707-3.157) 0.293 NA NA
Ages 0.976 (0.948-1.005) 0.109 NA NA
Prescribed DoseGy 0.951 (0.915-0.988) 0.011 0.943 (0.905-0.982) 0.005*
Chemotherapy 4.434 (1.066-18.440) 0.041 4.024 (0.951-17.032) 0.059*
Smoking 3.514 (0.842-14.674) 0.085 NA NA
COPD 0.618 (0.322-1.187) 0.148 NA NA
CVD 0.662 (0.328-1.335) 0.249 NA NA
Hypertension 0.441 (0.230-0.846) 0.014 0.464 (0.237-0.906) 0.025*
Histology 1.251 (0.952-1.645) 0.109 NA NA
KPS 1.023 (0.989-1.059) 0.191 NA NA
Stage 1.915 (0.995-3.686) 0.052 NA NA
GTV volumeCC 1.002 (1.000-1.003) 0.044 1.001 (0.999-1.002) 0.319*
Location 0.440 (0.182-1.065) 0.069 NA NA
Mean heart doseGy 1.053 (1.021-1.085) 0.001 1.041 (1.004-1.079) 0.028
Heart V5Gy 1.018 (1.007-1.029) 0.001 1.016 (1.003-1.029) 0.019
Heart V30Gy 1.025 (1.008-1.042) 0.004 1.018 (0.999-1.036) 0.061
Heart V55Gy 1.072 (1.035-1.111) <0.001 1.053 (1.010-1.098) 0.016
Mean Pericardial doseGy 1.066 (1.028-1.105) 0.001 1.050 (1.009-1.093) 0.016
Pericardial V5Gy 1.026 (1.011-1.041) 0.001 1.022 (1.004-1.039) 0.014
Pericardial V30Gy 1.033 (1.013-1.052) 0.001 1.022 (1.002-1.043) 0.030
Pericardial V55Gy 1.056 (1.024-1.088) <0.001 1.039 (1.005-1.074) 0.022
Abbreviations: COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; NSCLC NOS: non-small cell lung cancer, not 
otherwise specified; KPS: Karnofsky performance status; PCE: pericardial effusion; GTV: gross tumor volume. NA= not applicable, as it was not 
tested due to their limited significance under univariable analysis. The dosimetric parameter was entered into multivariable analysis separately one 
by one, not together.
Asterisk (*) represent average HR (95% CI) and P values.
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Table 3
Univariable and multivariable cox regression analysis for survival
Factors
Univariable analysis Multivariable analysis
HR (95% CI) P value HR (95% CI) P value
Gender 0.481 (0.239-0.968) 0.040 0.512 (0.252-1.039) 0.064*
Ages 1.019 (0.999-1.039) 0.062 NA NA
Prescribed DoseGy 0.958 (0.933-0.984) 0.002 0.963 (0.936-0.990) 0.009*
Chemotherapy 0.887 (0.485-1.622) 0.698 NA NA
Smoking 1.302 (0.646-2.622) 0.460 NA NA
COPD 0.753 (0.474-1.196) 0.229 NA NA
CVD 0.967 (0.607-1.539) 0.886 NA NA
Hypertension 1.351(0.851-2.145) 0.202 NA NA
Histology 1.122 (0.934-1.349) 0.220 NA NA
KPS 0.973 (0.951-0.996) 0.020 0.973 (0.949-0.997) 0.029*
Stage 1.293 (0.914-1.829) 0.147 NA NA
GTV volumeCC 1.001 (1.000-1.002) 0.192 NA NA
Location 0.655 (0.381-1.129) 0.128 NA NA
Mean heart doseGy 1.014 (0.992-1.036) 0.217 NA NA
Heart V5Gy 1.004 (0.997-1.012) 0.262 NA NA
Heart V30Gy 1.009 (0.996-1.022) 0.170 NA NA
Heart V55Gy 1.022 (0.991-1.053) 0.162 NA NA
Mean Pericardial doseGy 1.021 (0.997-1.040) 0.082 NA NA
Pericardial V5Gy 1.006 (0.996-1.015) 0.232 NA NA
Pericardial V30Gy 1.014 (1.001-1.027) 0.035 1.019 (1.004-1.033) 0.010
Pericardial V55Gy 1.024 (1.002-1.047) 0.032 1.030 (1.006-1.054) 0.014
PCE events (yes or no) 0.732 (0.458-1.170) 0.192 NA NA
Abbreviations: COPD: chronic obstructive pulmonary disease; CVD: cardiovascular disease; NSCLC NOS: non-small cell lung cancer, not 
otherwise specified; KPS: Karnofsky performance status; PCE: pericardial effusion; GTV: gross tumor volume. NA= not applicable, as it was not 
tested due to their limited significance under univariable analysis. The dosimetric parameter was entered into multivariable analysis separately one 
by one, not together.
Asterisk (*) represent average HR (95% CI) and P values.
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